Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women
Combined therapy vs. monotherapy was associated with a lower risk of all-cause mortality in patients regardless of sex. Nevertheless, a higher benefit was observed in women regarding men.
Authors
- David García‐Vega (ORCID: https://orcid.org/0009-0002-5218-4852)
- Sergio Cinza‐Sanjurjo (ORCID: https://orcid.org/0000-0002-4486-2820)
- José Ramón González‐Juanatey (ORCID: https://orcid.org/0000-0001-9681-3388)
- Sonia Eirás (ORCID: https://orcid.org/0000-0001-7200-253X)
- Carlos Tilves-Bellas
Institutions
- Universidade de Santiago de Compostela (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Centro de Investigación Biomédica en Red (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
Publication Details
- Journal
- Nutrition Metabolism and Cardiovascular Diseases
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1016/j.numecd.2025.104483
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00